Freedom of Information request on Does the MHRA take a proactive approach to classifying or taking action against products? (FOI 22/569)
Published 1 June 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-21-march-2022/freedom-of-information-request-on-does-the-mhra-take-a-proactive-approach-to-classifying-or-taking-action-against-products-foi-22569
FOI 22/569
25th March 2022
Dear
Thank you for your email.
Please find below answers to the questions you have raised in blue below.
-
Does the MHRA take a proactive approach to classifying or taking action against products? In other words, does the MHRA voluntarily and actively engage in market surveillance and subsequently take action on its own volition towards specific products, even when no complaints have been received regarding said products? Can the MHRA act without receiving any complaints? Or must the MHRA receive complaints regarding specific products in order to formally classify or take any action against said products? The MHRA can take a proactive approach as well as act on complaints received in regards to the classification of products.
-
If a MHRA Borderline Classifier is presented with products that are dangerous, as well as with extensive evidence that said products are dangerous, must he or she take action even if no complaint regarding said products has been received? All referrals and complaints about potential breaches of The Human Medicines Regulations 2012 are reviewed and dealt with by the MHRA.
If you have a query about the information provided, please reply to this email
If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: [email protected]
Due to the ongoing Pandemic situation, we are not able to accept delivery of any documents or correspondence by post or courier to any of our offices
Please remember to quote the reference number above in any future communications.
If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:
Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Yours sincerely
MHRA Customer Experience Centre
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 0203 080 6000